New cream shows promise for clearing psoriasis in chinese patients

NCT ID NCT06648772

Completed Disease control Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This Phase 3 study tests a cream called roflumilast (Zoryve) for treating plaque psoriasis in Chinese patients aged 6 years and older. The cream is applied once daily to reduce skin plaques. Researchers will measure how many patients achieve clear or almost clear skin after 8 weeks, compared to a placebo cream. The study also checks for side effects and how the body processes the medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Roflumilast cream 0.3% (Zoryve)
What this could lead to: If successful, this could offer a new topical treatment option for plaque psoriasis in China, potentially improving skin clearing with a once-daily cream.
What could go wrong: This is a Phase 3 trial, but results may not match earlier studies. Side effects like skin irritation or application-site reactions are possible. The cream may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLAQUE PSORIASIS

Contacts and locations

Show contact details

Locations

Affiliated Hospital of Chengde Medical College

Chengde, China
Affiliated Hospital of Chongqing Three Gorges Medical College

Chongqing, China
Affiliated Hospital of Jiangsu University

Zhenjiang, China
Affiliated Hospital of Nantong University

Nantong, China
Beijing Children's Hospital, Capital Medical University

Beijing, China
Beijing Tongren Hospital, Capital Medical University

Beijing, China
Children's Hospital of Hunan Province

Changsha, China
Dermatology Hospital of Southern Medical University

Guangzhou, China
Enshi Tujia and Miao Autonomous Prefecture Central Hospital

Enshi, China
Hainan Fifth People's Hospital

Haikou, China
Ji'nan Central Hospital

Ji'nan, China
People's Hospital of Peking University

Beijing, 100032, China
Sanmenxia Central Hospital

Sanmenxia, China
Shanghai Skin Disease Hospital

Shanghai, China
Shengjing Hospital of China Medical University

Shenyang, Liaoning, China
Sichuan Provincial People's Hospital

Chengdu, China
The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, China
The First Hospital of Jilin University

Jilin City, China
The First People's Hospital of Hangzhou

Hangzhou, China
The First People's Hospital of Yancheng

Yancheng, China
The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Jinhua, China
The Second Affiliated Hospital of Chongqing Medical University

Chongqing, China
The Second Affiliated Hospital of Harbin Medical University

Harbin, China
The Second Affiliated Hospital of Henan University of Science and Technology

Luoyang, China
The Second Affiliated Hospital of South Anhui Medical College

Wuhu, China
The Second Affiliated Hospital of Xi'an Jiaotong University

Xi'an, China
The Second People's Hospital of Chengdu

Chengdu, China
The Second Xiangya Hospital of Central South University

Changsha, China
The Sixth People's Hospital of Dongguan

Dongguan, China
Zhejiang Provincial People's Hospital

Hangzhou, China
Zhengzhou Central Hospital

Zhengzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.